NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $1.26 -0.01 (-0.79%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.23▼$1.3250-Day Range$1.07▼$1.7552-Week Range$0.73▼$3.28Volume665,336 shsAverage Volume1.03 million shsMarket Capitalization$119.86 millionP/E RatioN/ADividend YieldN/APrice Target$3.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Assertio alerts: Email Address Assertio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside172.8% Upside$3.44 Price TargetShort InterestBearish6.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 4 Articles This WeekInsider TradingAcquiring Shares$11,100 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.17) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.33 out of 5 starsMedical Sector458th out of 910 stocksPharmaceutical Preparations Industry213th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has only been the subject of 2 research reports in the past 90 days.Read more about Assertio's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.54% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Assertio has recently increased by 0.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASRT. Previous Next 2.3 News and Social Media Coverage News SentimentAssertio has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Assertio this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for ASRT on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows18 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.17) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Assertio Stock (NASDAQ:ASRT)Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More ASRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASRT Stock News HeadlinesSeptember 3, 2024 | globenewswire.comAssertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024August 28, 2024 | americanbankingnews.comAssertio Holdings, Inc. (NASDAQ:ASRT) Receives $3.44 Consensus Target Price from BrokeragesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 21, 2024 | markets.businessinsider.comAssertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic GrowthAugust 10, 2024 | insidermonkey.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Assertio Therapeutics on Strong Financials and Market PositionAugust 7, 2024 | globenewswire.comAssertio Reports Second Quarter 2024 Financial ResultsAugust 2, 2024 | morningstar.comAssertio Holdings Inc ASRTSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.July 27, 2024 | msn.comMaxim Group Initiates Coverage of Assertio Holdings (ASRT) with Buy RecommendationJuly 24, 2024 | globenewswire.comAssertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024July 24, 2024 | finance.yahoo.comBuxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.July 9, 2024 | globenewswire.comAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 3, 2024 | globenewswire.comASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 24, 2024 | 247wallst.com3 Penny Stocks With 458% Average Upside According to Wall Street AnalystsJune 6, 2024 | globenewswire.comAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2024 | globenewswire.comAssertio to Participate in the Sidoti Small Cap Conference on June 12, 2024May 29, 2024 | markets.businessinsider.comAssertio Names O'Grady CEOSee More Headlines Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$3.44 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+172.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-331,940,000.00 Net Margins-261.08% Pretax Margin-203.27% Return on Equity4.88% Return on Assets2.37% Debt Debt-to-Equity Ratio0.29 Current Ratio1.93 Quick Ratio1.51 Sales & Book Value Annual Sales$132.19 million Price / Sales0.91 Cash Flow$0.78 per share Price / Cash Flow1.62 Book Value$1.39 per share Price / Book0.91Miscellaneous Outstanding Shares95,125,000Free Float92,081,000Market Cap$119.86 million OptionableOptionable Beta0.79 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Heather L. Mason (Age 64)Interim CEO & Director Comp: $92.5kMr. Ajay Patel (Age 40)Senior VP & CFO Comp: $538.79kMr. Paul Schwichtenberg (Age 53)Senior Vice President & Chief Commercial Officer Comp: $573.65kMr. Bill IskosSenior Vice President of OperationsMs. Molly DirSenior Vice President of HR & Administration ?Mr. Sam Schlessinger (Age 42)Senior VP & General Counsel Dr. Howard J. Franklin M.B.A.M.D., Senior Vice President of MedicalMore ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAC4 TherapeuticsNASDAQ:CCCCKorro BioNASDAQ:KRROTourmaline BioNASDAQ:TRMLFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsAQR Capital Management LLCSold 922,756 shares on 8/15/2024Ownership: 2.426%Point72 Asia Singapore Pte. Ltd.Bought 120,088 shares on 8/15/2024Ownership: 0.126%Marshall Wace LLPBought 56,500 shares on 8/14/2024Ownership: 0.059%Point72 DIFC LtdBought 31,929 shares on 8/14/2024Ownership: 0.034%Renaissance Technologies LLCBought 285,655 shares on 8/9/2024Ownership: 2.499%View All Insider TransactionsView All Institutional Transactions ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $1.07 at the start of the year. Since then, ASRT shares have increased by 17.8% and is now trading at $1.26. View the best growth stocks for 2024 here. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. The company had revenue of $31.13 million for the quarter, compared to analyst estimates of $30.37 million. Assertio had a positive trailing twelve-month return on equity of 4.88% and a negative net margin of 261.08%. Who are Assertio's major shareholders? Top institutional shareholders of Assertio include Renaissance Technologies LLC (2.50%), AQR Capital Management LLC (2.43%), Perritt Capital Management Inc (0.45%) and Bank of New York Mellon Corp (0.37%). Insiders that own company stock include Daniel A Peisert, William Mckee, Heather L Mason, Jeff L Vacirca, Ajay Patel, Sam Schlessinger and Paul Schwichtenberg. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN) and This page (NASDAQ:ASRT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.